Arthur Jeng
Infectious Disease · Sylmar, CANPI 1013070499
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $625,992 of the $765,656 with a category attached, or 81.8%. It is spread thinly across 15 manufacturers, the largest accounting for just 22.3%. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,193 payments — averaging $641.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$171K
- Pfizer$148K
- Merck$94K
- Astellas Pharma US Inc$82K
- Ferring Pharmaceuticals Inc.$64K
- Melinta Therapeutics, LLC$63K
- plus $142K from 9 others
Across 15 payments — averaging $13,620 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$127K
- Biofire Diagnostics, LLC$74K
- Biomerieux Inc$2K
- Melinta Therapeutics, LLC$1K
What the payments were for
- Consulting fees$29,0024%
- Speaking & faculty fees$625,99282%
- Travel & lodging$80,80811%
- Food & beverage$27,8074%
- Education$2,0460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 215 | $171,122 |
| Pfizer(2 entities) | 212 | $148,411 |
| Merck | 123 | $93,872 |
| Astellas Pharma US Inc | 162 | $82,499 |
| Ferring Pharmaceuticals Inc. | 163 | $64,337 |
| Melinta Therapeutics, LLC | 101 | $62,947 |
| La Jolla Pharmaceutical Company | 46 | $26,017 |
| Biomerieux Inc | 10 | $23,059 |
| Tetraphase Pharmaceuticals, Inc. | 27 | $22,513 |
| Paratek Pharmaceuticals, Inc. | 45 | $21,621 |
| Amgen | 40 | $18,150 |
| Dynavax Technologies Corporation | 18 | $17,612 |
| Biofire Diagnostics, LLC | 4 | $7,328 |
| AbbVie(2 entities) | 26 | $6,145 |
| Gilead | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fetroja$149,688
- ZERBAXA$78,741
- CRESEMBA$72,600
- ABRYSVO$55,490
- REBYOTA$49,970
- Xerava$33,974
- PREVNAR 20$32,917
- Kimyrsa$32,812
- Vabomere$27,392
- NUZYRA$20,896
- Enbrel$17,576
- Heplisav-B$17,198
- FilmArray BCID Panel$14,233
- PREVNAR - 13$13,067
- BPN14770$10,620
- COMIRNATY$10,306
- PENBRAYA$10,246
- Zevtera$10,109
- FILMARRAY PNEUMONIA PANEL (PNEUMO)$8,715
- RECARBRIO$6,690
How this compares
$765,656 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $60,446 |
| JulucaDolutegravir/Rilpivirine | 14 | $44,641 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $505 |
| Gabapentin | 16 | $81 |
| Tamsulosin Hcl | 13 | $59 |
| Latanoprost | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $24 | $60,44615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in Sylmar
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
- Shawn HasslerSan Francisco$433K
- David AsmuthSacramento$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.